PureTech Health plc (LSE: PRTC) issued 159,251 ordinary shares to executives on Sunday following the vesting of restricted share units under the company’s Performance Share Plan, according to a regulatory filing.
The shares were distributed after payroll tax deductions, with Eric Elenko, the company’s President, receiving 98,132 shares. Charles Sherwood, Chief Operating Officer, General Counsel and Corporate Secretary, received 41,100 shares, while Michael Inbar, Chief Accounting Officer, received 20,019 shares.
The RSUs, originally granted on November 19, 2025, vested on August 1, 2026. The issue price was set at 0.01 GBP per share, reflecting the nominal value. Payroll taxes were calculated using a market reference price of 121.13 pence per share, derived from the average closing price over the three trading days prior to issuance.
Following the transaction, PureTech’s total issued ordinary share capital rose to 257,927,489 shares, while treasury holdings stood at 12,747,843 shares. The issuance was conducted in compliance with Article 19 of the EU Market Abuse Regulation, as disclosed in the filing.
